The Korean Patent Court’s recent decision on medical use inventions emphasizes the importance of disclosing concrete pharmacological data and raises the bar for prior-published clinical trial protocols as prior art.
July 2020, Managing IP
The Korean Patent Court’s recent decision on medical use inventions emphasizes the importance of disclosing concrete pharmacological data and raises the bar for prior-published clinical trial protocols as prior art.
July 2020, Managing IP